Address
2nd Floor, Meadows Office Complex, 201 Route 17 North
RUTHERFORD, NJ 07070
United States
Cancer Genetics, Inc. (CGI) is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.RUTHERFORD, NJ 07070
United States
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | 25.08% | -658.64% |
| Operating margin | -137.63% | -271.08% |
| EBITD margin | - | -258.83% |
| Return on average assets | 16.31% | -322.49% |
| Return on average equity | - | - |
| Employees | 48 | - |
| Carbon Disclosure Rating | - | - |
No comments:
Post a Comment